Humacyte Stock News

– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest.

DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company's Board of Directors, both of whom bring substantial experience in the area...

– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that devel...

– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –

– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –

– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel –

– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 –